IART Integra LifeSciences Holdings Corporation

Integra LifeSciences to participate in the Piper Jaffray 31st Annual Healthcare Conference

Integra LifeSciences to participate in the Piper Jaffray 31st Annual Healthcare Conference

PRINCETON, N.J., Nov. 25, 2019 (GLOBE NEWSWIRE) -- (NASDAQ: IART), a leading global medical technology company, announced today that Carrie Anderson, chief financial officer, will present at the Piper Jaffray 31st Annual Healthcare Conference in New York City on Wednesday, December 4, 2019 at 8:00 a.m. EST.  

About Integra LifeSciences

Integra LifeSciences is a global leader in regenerative technologies, neurosurgical and extremity orthopedic solutions dedicated to limiting uncertainty for clinicians, so they can focus on providing the best patient care. Integra offers a comprehensive portfolio of high quality, leadership brands that include AmnioExcel®, Bactiseal®, Cadence®, Certas™, Codman®, CUSA®, DuraGen®, DuraSeal®, ICP Express®, Integra®, MediHoney®, MicroFrance®, PriMatrix®, Salto Talaris®, SurgiMend®, TCC-EZ®, Titan™ and VersaTru™. For the latest news and information about Integra and its brands, please visit .

Statements made at the upcoming conferences may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ from predicted results. Forward-looking factors that may be discussed include, but are not limited to, future financial performance, new product development, governmental approvals, market potential and resulting sales as well as potential therapeutic applications, and additional acquisitions. These risks and uncertainties include market conditions and other factors beyond the Company's control and the economic, competitive, governmental, technological and other factors identified under the heading "Risk Factors" included in item 1A of Integra's Annual Report on Form 10-K for the year ended December 31, 2018 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results. These forward-looking statements are made only as the date thereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations Contacts:

Sravan Emany

Senior Vice President – Strategy, Treasury & Investor Relations

(609) 936-2488

 

Michael Beaulieu

Director, Investor Relations

(609) 750-2827

 

Media Contact:

Laurene Isip

Senior Director, Global Corporate Communications

(609) 750-7984

 

EN
25/11/2019

Underlying

Reports on Integra LifeSciences Holdings Corporation

 PRESS RELEASE

Integra LifeSciences Leadership to Present at the Citi 2025 Global Hea...

Integra LifeSciences Leadership to Present at the Citi 2025 Global Healthcare Conference PRINCETON, N.J., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced that chief executive officer Mojdeh Poul and chief financial officer Lea Knight will present at the Citi 2025 Global Healthcare Conference on December 3, 2025 at 10:30 a.m ET A live webcast of the presentation will be available on the Integra LifeSciences investor relations website under . About Integra LifeSciencesAt Integra LifeSc...

 PRESS RELEASE

Integra LifeSciences Welcomes Policy Advancements Supporting Medicare ...

Integra LifeSciences Welcomes Policy Advancements Supporting Medicare Beneficiary Access Company to advance care through broader access to breadth of skin substitutes across four unique technology platforms PRINCETON, N.J., Nov. 25, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: IART), a leading global medical technology company, commends the Centers for Medicare & Medicaid Services (CMS) on its Calendar Year 2026 Medicare Physician Fee Schedule and Outpatient Prospective Payment System rules. All Integra dermal regenerative templates, decellularized dermal scaffolds and amniotic tissue membranes, ...

 PRESS RELEASE

Integra LifeSciences Receives FDA 510(k) Clearance for Use of the CUSA...

Integra LifeSciences Receives FDA 510(k) Clearance for Use of the CUSA® Clarity Ultrasonic Surgical Aspirator System for Cardiac Surgeries PRINCETON, N.J., Nov. 11, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: IART), a leading global medical technology company, is pleased to announce the FDA 510(k) clearance for use of its for cardiac surgeries. The recent clearance for specific cardiac indications encompasses the debridement of unwanted tissue in cardiac surgeries, including valve replacement and repair. In addition to cardiac surgery, the CUSA Clarity Ultrasonic Surgical Aspirator System is ind...

 PRESS RELEASE

Integra LifeSciences Reports Third Quarter 2025 Financial Results

Integra LifeSciences Reports Third Quarter 2025 Financial Results PRINCETON, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today reported financial results for the third quarter ending September 30, 2025. Third Quarter 2025 Highlights Third quarter revenues of $402.1 million increased 5.6% on a reported basis and 5.0% on an organic basis compared to the prior year. Third quarter GAAP earnings per diluted share of $(0.07), compared to $(0.14) in the prior year. Adjusted earnings per diluted s...

 PRESS RELEASE

Integra LifeSciences to Host Third Quarter 2025 Financial Results Conf...

Integra LifeSciences to Host Third Quarter 2025 Financial Results Conference Call on October 30, 2025 PRINCETON, N.J., Oct. 15, 2025 (GLOBE NEWSWIRE) --  (Nasdaq: IART), a leading global medical technology company, will release third quarter 2025 financial results on Thursday, October 30, 2025, prior to the market open. In conjunction with the earnings release, Integra’s management team will host a conference call at 8:30 a.m. ET. A live webcast will be available on the Investors section of the Company’s website at . For those planning to participate on the call, register  to receive dia...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch